PT-141 (Bremelanotide): Research-Only vs. Medical-Grade Compounding Pharmacy Guide

Print or save as PDFOpens the printable medication review sheet and your print dialog. No sign-up.

What research-only PT-141 actually is

Products sold as research-use PT-141 are not Vyleesi and are not FDA-approved drugs [3][1]. A research-use label does not turn the contents into an approved drug.

So three different things get called PT-141:

• Vyleesi, the FDA-approved bremelanotide autoinjector [1]
• Compounded bremelanotide, prepared by a pharmacy under one of the federal compounding pathways [4]
• Research-use PT-141, sold as a laboratory chemical [3]

Only the first has been through FDA review as a drug.

What the FDA-approved product is

Vyleesi is bremelanotide 1.75 mg in a prefilled autoinjector for subcutaneous injection, prescription only [1][2]. It is approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder, meaning low desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug [1]. Acquired means the problem developed in a woman who previously had no trouble with sexual desire; generalized means it occurs regardless of stimulation, situation or partner [1]. The label states it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1].

Bremelanotide is a cyclic peptide of 7 amino acids and a melanocortin receptor agonist that nonselectively activates several receptor subtypes, in this order of potency: MC1R, MC4R, MC3R, MC5R, MC2R [1]. At therapeutic doses, binding at MC1R and MC4R matters most, and how the drug improves HSDD is unknown [1]. MC1R sits on pigment cells, so binding there increases pigmentation [1].

The label dose is 1.75 mg injected into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. The label says not to give more than one dose within 24 hours and that more than 8 doses a month is not recommended [1]. It also says to stop after 8 weeks if there is no improvement in symptoms, and that the duration of effect after a dose is unknown [1]. There is no boxed warning and no REMS [1][2].

What the trials behind the approval showed

Two identical 24-week randomized, double-blind, placebo-controlled trials (RECONNECT, NCT02333071 and NCT02338960) randomized 1,267 premenopausal women with HSDD, 1:1, to bremelanotide 1.75 mg as needed or placebo. Of those, 1,247 were in the safety population and 1,202 in the efficacy analysis, with a mean age of 39 [5].

Desire on the FSFI desire domain improved more than placebo, by 0.30 points in study 301, 0.42 in study 302 and 0.35 integrated across both, all statistically significant, and distress related to low desire fell too [5]. The label reports mean FSFI desire changes from baseline of 0.5 vs 0.2 in study 1 and 0.6 vs 0.2 in study 2 [1]. The trials found no significant difference in the number of satisfying sexual events [5].

Can bremelanotide be compounded?

Compounded bremelanotide is not an FDA-approved drug. Federal law has different compounding pathways: for one, a valid patient-specific prescription is required, and outsourcing facilities may distribute compounded drugs in response to an order from a health care provider, such as a hospital [4]. FDA reports that it has investigated many cases of serious patient injury linked to poor quality compounded drugs in general, including contaminated drugs from a Massachusetts pharmacy in 2012 that led to more than 750 cases of infection and more than 60 deaths across 20 states [4].

Bremelanotide's standing on FDA's bulk-substance lists is specific. It does not appear on FDA's page of bulk substances that may present significant safety risks when compounded (content dated 04/22/2026), it does not appear in any category on FDA's bulk-substance lists, and it is not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [6][7][8]. Absence from a risk list is not a finding that a compounded product is safe.

What the label says to watch for

Blood pressure and heart rate. Each dose transiently raises blood pressure and lowers heart rate. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a heart rate reduction of up to 5 beats per minute; values usually returned to baseline within 12 hours, and repeat daily dosing 24 hours apart for up to 16 days showed no additive effect [1]. These are maximal, not average, figures. In an open-label ambulatory study of 127 premenopausal women dosed once daily for 8 days, the mean daytime increase was 1.9 mmHg systolic (95% CI 1.0 to 2.7) and 1.7 mmHg diastolic (95% CI 0.9 to 2.4), with a mean heart rate decrease of 0.5 beats per minute [1]. Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease and is not recommended for patients at high risk for cardiovascular disease [1].

Nausea. Reported by 40.0% of patients on bremelanotide vs 1.3% on placebo in the pooled phase 3 trials; 13% of treated patients took an anti-nausea medicine and 8% stopped the trials because of it, and it was highest after the first dose (21%) before falling to about 3% with later doses [1]. Pre-treating with oral ondansetron did not reduce nausea in a phase 4 single-dose study of 228 healthy women, and the label says it is not recommended [1].

Focal hyperpigmentation. Darkening of skin, gums or breasts, including the face, was reported by 1% of patients taking up to 8 doses a month vs none on placebo. In another study, 38% of patients developed it after daily dosing for 8 days and a further 14% after 8 more consecutive days, with higher risk in darker skin and with daily dosing, and resolution was not confirmed in all patients [1]. The label says to consider discontinuing Vyleesi if hyperpigmentation develops [1].

Other reactions. In at least 2% of patients and more than placebo: flushing 20.3% vs 0.3%, injection site reactions 13.2% vs 8.4%, headache 11.3% vs 1.9%, vomiting 4.8% vs 0.2% [1]. Eighteen percent of patients stopped treatment because of adverse reactions vs 2% on placebo, and serious adverse reactions occurred in 1.1% vs 0.5% [1].

Interactions. The label says to avoid Vyleesi with oral naltrexone products intended to treat alcohol or opioid addiction, and notes that Vyleesi may slow stomach emptying and reduce absorption of oral medicines [1].

Is PT-141 approved for men?

No. The label states Vyleesi is not indicated for HSDD in men [1]. The published male data come from an older intranasal formulation: a double-blind, placebo-controlled study in healthy men and in sildenafil-responsive men with erectile dysfunction found a statistically significant erectile response versus placebo at intranasal doses above 7 mg, with flushing and nausea the most common adverse events [9]. Intranasal PT-141 is not the approved product [1].

Bottom line

Only Vyleesi is an FDA-approved bremelanotide product, and its label covers premenopausal women with acquired, generalized HSDD, not men or postmenopausal women [1][2]. Research-use and pharmacy-prepared bremelanotide are separate regulatory categories from each other and from an approved drug [3][4].